Gastroesophageal Junction Adenocarcinoma

Gastroesophageal Junction Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

695 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 228
Recruiting: 123
Ph III recruiting: 18
Growth YoY: +39.5%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (82)

clinicaltrialsPublishedShowing 101–150 of 695 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04523818	Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma	active not recruiting	Phase 1	25	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT05041153	Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	active not recruiting	Early Phase 1	15	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials